Key Takeaways:
A securities class action lawsuit against GeneDx Holdings Corp. and certain officers alleges the company misled investors about its Fabric Genomics acquisition, following a 49% stock collapse on May 5 that erased more than $33 a share.
"The company's statements concerning its business, operations, and prospects lacked a reasonable factual basis," the complaint filed in the US District Court for the District of Connecticut alleges, according to court documents reviewed by Edgen. The lawsuit covers investors who bought GeneDx securities between April 16, 2025 and May 4, 2026.
GeneDx shares fell $33.42, or 49.2%, on May 5 after the company reported first-quarter 2026 results that showed adjusted gross margin dropping to 69% from 74% and a $31.2 million impairment charge tied to its prior acquisition of Fabric Genomics, an AI-driven genomic interpretation company. The company also lowered its full-year revenue guidance to $475 million to $490 million, down from a prior range of $540 million to $550 million.
The complaint alleges GeneDx failed to disclose that the company may have misled investors about Fabric Genomics' importance, that its average reimbursement rates were not as durable as previously stated, and that gross margins would decline as a result. The company had touted the Fabric acquisition as expected to expand its addressable market through multiple scalable revenue streams and transform static data into a recurring revenue-generating platform.
At least three law firms — Bronstein, Gewirtz & Grossman, The Gross Law Firm, and Hagens Berman — have announced investigations or filed claims on behalf of shareholders. Investors have until Aug. 3 to petition the court to serve as lead plaintiff.
The 49% single-day decline puts GeneDx shares at their lowest level since the company's restructuring, testing support near pre-acquisition valuations. The next catalyst for the stock will be the lead plaintiff appointment hearing, which will determine which investor group directs the litigation strategy.
This article is for informational purposes only and does not constitute investment advice.
